



May 3, 2023

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex Bandra (East) <u>Mumbai – 400 051</u> Stock Code : INDOCO-EQ	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, <u>Mumbai – 400 001</u> Stock Code : 532612
---	---

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Closure of USFDA Inspection at Indoco Remedies Limited's Solid Oral Formulation Facility (Plant 1) at Goa

Dear Sir/Madam,

Further to the intimation dated January 23, 2023, on the audit conducted by the United States Food and Drug Administration (USFDA) at our Solid Oral Formulation Facility (Plant 1) at Goa, from January 16, 2023 to January 20, 2023, the Company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection.

Please find enclosed herewith press release in this regard.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For Indoco Remedies Limited



Ramanathan Hariharan
Company Secretary & Head- Legal



PRESS RELEASE

Indoco receives EIR for its manufacturing facility in Goa (Plant I)

Mumbai, May 3, 2023: Indoco Remedies Ltd. announced today the receipt of an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the US Food and Drug Administration (USFDA) for their facility for solid dosages (Plant I) located in Verna, Goa.

The recent inspection held from January 16, 2023, to January 20, 2023, was a surveillance inspection.

The receipt of the EIR with VAI status also signifies the imminent closeout of the Warning Letter issued by the USFDA in July 2019 for the manufacturing site, situated at L-14, Verna Industrial Road, Goa (Plant I).

Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.

Commenting on this positive development, Ms. Aditi Kare Panandikar, Managing Director – Indoco Remedies Ltd., said, "We are happy to receive the EIR in three and a half months' time from the date of inspection. It is very encouraging that the site has been endorsed with VAI status, from (Official Action Indicated) OAI status, by the US Regulators.

We are committed to maintaining strict adherence to the highest quality standards and to ensuring delivery of safe and effective generic medicines to our patients in the U.S. and around the world."

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 198 million Company, employs over 6000 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility in Hyderabad. The facilities have been approved by various Regulatory Authorities, including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 83 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 8 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritional, Cardiovascular, Anti-Diabetics, Pain Management, Gynecology, etc. Top Indoco brands include Cyclopan, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensiform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexitin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.



For more details on Indoco, you may visit www.indoco.com

For media inquiries please contact:

Pramod Ghorpade

Mobile: 9619883225

E-mail: pramod.ghorpade@indoco.com / corpcom@indoco.com

INDOCO REMEDIES LIMITED

Indoco House, 166, C.S.T. Road, Kalina, Santacruz (E), Mumbai 400098, India.
Tel. No.: +91 22 6287 1000 / 6879 1250 ■ CIN: L85190MH1947PLC005913

www.indoco.com